NEVVI Medicare utilization intelligence
or

← back

Provider profile

SAMAHA, TONY MD

Hematology-Oncology · NPI 1891767208 · WORCESTER, MA

1
Groups
28
Codes · 2024
34,849
Disclosed services

SAMAHA, TONY is a Hematology-Oncology in WORCESTER, MA, a member of 1 medical group, who billed 28 distinct codes to Medicare Part B in 2024.

Groups: RELIANT MEDICAL GROUP INC (WORCESTER, MA)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

34,849
disclosed services
28
codes billed to Medicare Part B
Prior year · CY2023 59,605 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1756 Injection, iron sucrose, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
J1745 Injection, infliximab, excludes biosimilar, 10 mg
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J2469 Injection, palonosetron hcl, 25 mcg
96375 Injection of additional new drug or substance into vein
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
96413 Administration of chemotherapy into vein, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
96372 Injection of drug or substance under skin or into muscle
J3490 Unclassified drugs
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96374 Injection of drug or substance into vein
96415 Administration of chemotherapy into vein, each additional hour
96523 Irrigation of implanted venous access drug delivery device
99221 Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96417 Administration of additional new drug or substance into vein, 1 hour or less
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.